Information de reference pour ce titreAccession Number: | 01451458-201306010-00017.
|
Author: | Levy, Emily R. 1; McCarty, James M. 2,3; Shane, Andi L. 4; Weintrub, Peggy S. 5
|
Institution: | (1)Department of Pediatrics, University of California, San Francisco (2)Children's Hospital Central California, Madera (3)University of California, San Francisco Medical Education Program, Fresno (4)Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia (5)Division of Infectious Disease, Department of Pediatrics, University of California, San Francisco
|
Title: | |
Source: | Clinical Infectious Diseases. 56(11):1573-1578, June 1, 2013.
|
Abstract: | Background. Coccidioidomycosis is a spectrum of diseases caused by the dimorphic fungi Coccidioides. Current regimens for severe or disseminated disease include fluconazole, itraconazole, or amphotericin; newer triazoles (ie, voriconazole, posaconazole) have been demonstrated to be useful in refractory disease. Previous reported experience with combination triazole and caspofungin therapy has been very limited; however, the utility of this combination for treatment of other invasive fungal diseases suggests potential benefit in refractory coccidioidomycosis.
Methods. We conducted a retrospective review of 9 pediatric patients treated with combination voriconazole and caspofungin (V/C) salvage therapy for refractory coccidioidomycosis at two children's hospitals between January 2000 and June 2012.
Results. Nine children with refractory coccidioidomycosis were treated with V/C salvage therapy after failing conventional therapy consisting of a triazole, amphotericin B, or a combination of both. Eight of the 9 patients are currently in remission; 1 patient with central nervous system involvement continues to progress.
Conclusions. We report our positive clinical experience treating medically refractory coccidioidomycosis in the pediatric population with concurrent voriconazole and caspofungin therapy. Additional in vitro and in vivo evaluations are warranted to support the role of V/C salvage therapy for refractory coccidioidomycosis.
(C) Copyright Oxford University Press 2013.
|
Author Keywords: | refractory; coccidioidomycosis; voriconazole; caspofungin; pediatrics.
|
References: | 1. Hector RF, Rutherford GW, Tsang CA, et al. The public health impact of coccidioidomycosis in Arizona and California Int J Environ Res Public Health. 2011;8:1150-73
2. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis Clin Infect Dis. 2005;41:1217-23
3. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group Ann Intern Med. 2000;133:676-8
4. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations J Am Acad Dermatol. 1990;23(3 Pt 2):593-601
5. Diaz M, Negroni R, Montero-Gei F, et al. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group Clin Infect Dis. 1992;14(suppl 1):S68-76
6. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group Ann Intern Med. 1993;119:28-35
7. Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group Am J Med. 1995;98:249-56
8. Deresinski SC. Coccidioidomycosis: efficacy of new agents and future prospects Curr Opin Infect Dis. 2001;14:693-6
9. Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole Clin Infect Dis. 2004;39:e74-7
10. Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis Antimicrob Agents Chemother. 2004;48:2341
11. Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole Clin Infect Dis. 2011;53:1060-6
12. Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model Antimicrob Agents Chemother. 2001;45:1854-9
13. Cordeiro RA, Brilhante RS, Rocha MF, et al. In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from northeast, Brazil Mycopathologia. 2006;161:21-6
14. Park DW, Sohn JW, Cheong HJ, et al. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole BMC Infect Dis. 2006;6:26
15. Antony S. Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient Clin Infect Dis. 2004;39:879-80
16. Hsue G, Napier JT, Prince RA, Chi J, Hospenthal DR. Treatment of meningeal coccidioidomycosis with caspofungin J Antimicrob Chemother. 2004;54:292-4
17. Gonzalez GM, Gonzalez G, Najvar LK, Graybill JR. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model J Antimicrob Chemother. 2007;60:1341-6
18. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis Antimicrob Agents Chemother. 2002;46:2564-8
19. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far Drug Resist Updat. 2003;6:257-69
20. Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis Transpl Infect Dis. 2009;11:89-93
21. Thomas A, Korb V, Guillemain R, et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis J Clin Pharm Ther. 2010;35:49-53
22. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin J Infect Dis. 2003;187:1834-43
23. Shane AL, Weintrub PS. Voriconazole and caspofungin combination therapy for disseminated coccidioidomycosis in children 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, 6 October 2005. Abstract 586
24. Ampel NM. Coccidioidomycosis: a review of recent advances Clin Chest Med. 2009;30 241-51, v
25. Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections Antimicrob Agents Chemother. 2009;53:1648-51
26. Cao C, Liu W, Li R, Wan Z, Qiao J. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei J Antimicrob Chemother. 2009;63:340-2
27. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124:305-10
28. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001 Clin Infect Dis. 2003;37(suppl 3):S188-224
|
Language: | English.
|
Document Type: | ARTICLES AND COMMENTARIES.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 1058-4838
|
DOI Number: | https://dx.doi.org/10.1093/cid/c...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|